Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01352286 · ClinicalTrials.gov registry record · Phase 2
Redirected Auto T Cells for Advanced Myeloma
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT01352286 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 25 participants.
The verdict
NCT01352286, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to 1) evaluate the safety and tolerability of autologous genetically modified T cells transduced to express the high affinity NY-ESO-1c259 TCR in HLA-A2+ subjects and 2) measure the incidence of GVHD in patients following infusion of TCR modified autologous T cells.
Interventions
- GENETIC Autologous Genetically modified T cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2011-05-13 |
| Est. Completion | 2019-07-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01352286
The ClinicalTrials.gov registry entry for NCT01352286 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Autologous Genetically modified T cells is the first listed.
NCT01352286 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01352286 about?
NCT01352286 is a clinical study titled "Redirected Auto T Cells for Advanced Myeloma". The purpose of this study is to 1) evaluate the safety and tolerability of autologous genetically modified T cells transduced to express the high affinity NY-ESO-1c259 TCR in HLA-A2+ subjects and 2) measure the incidence of GVHD in patients following infusion of TCR modified autologous T cells.
What is the current status of trial NCT01352286?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2011-05-13. Estimated completion is 2019-07-08.
What interventions are being tested in trial NCT01352286?
The interventions under investigation include: Autologous Genetically modified T cells (GENETIC).
Who is sponsoring clinical trial NCT01352286?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.